Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
42 papers
This meta-analysis combined 241 effect sizes from 114 studies to test how six habitual emotion-regulation strategies relate to symptoms of anxiety, depression, eating disorders, and substance-related problems. Rumination showed the strongest (large) link with symptoms. Avoidance, problem solving, and suppression showed medium-to-large links, while reappraisal and acceptance showed smaller (small-to-medium)…
This small randomized trial tested a fully automated text-based conversational agent called Woebot as a way to deliver cognitive behavioral therapy to college-age young adults with symptoms of depression and anxiety. Over 2 weeks, the Woebot group (n=34) showed a statistically larger drop in depression scores (PHQ-9) than an information-only…
This 2001 review looked at studies on exercise, anxiety, depression, and stress. It found that short-term emotional effects of exercise are mixed, but many cross-sectional and longitudinal studies report that regular aerobic exercise training reduces anxiety and depression symptoms and may protect against the harmful effects of stress. The clearest…
This umbrella review looked at the best existing reviews and large studies to see if depression is linked to low serotonin or low serotonin activity. Across measures of serotonin in fluids, receptor and transporter studies, tryptophan depletion experiments, and large genetic studies, the evidence was mixed or absent. The authors…
This phase 3, double-blind trial tested whether continuing esketamine nasal spray plus an oral antidepressant could delay relapse in adults with treatment-resistant depression who had already improved after an initial esketamine course. Of 297 patients who entered the randomized phase, continuing esketamine reduced relapse compared with switching to placebo nasal…
A group of international mood-disorder experts reviewed the research on ketamine and esketamine for adults whose depression did not get better with usual antidepressants. They found that these drugs work differently from standard antidepressants and can lift symptoms more quickly for some people with treatment-resistant depression. However, the experts also…
Repeated ketamine infusions have cumulative and sustained antidepressant effects. Reductions in depressive symptoms were maintained among responders through once-weekly infusions. These findings provide novel data on efficacious administration strategies for ketamine in patients with treatment-resistant depression. Future studies should further expand on optimizing administration to better translate the use of…
Major depressive disorder (MDD) is defined without assuming a single cause and has two main symptoms: depressed mood and loss of interest or pleasure. The paper says we should also pay more attention to fatigue, sleep problems, anxiety, thinking (cognitive) problems, and sexual problems when diagnosing and judging treatment. Some…
The CANMAT 2023 update gives doctors clear, up-to-date advice for treating adults with major depressive disorder. It puts evidence into a practical, clinician-friendly format. The update says treatment should be a team effort between patients and clinicians, be tailored to each person, and follow a planned, systematic process with regular…
Researchers pooled results from 205 intravenous ketamine infusions (0.5 mg/kg given over 40 minutes) in 97 people with treatment-resistant major depression. About two thirds (67%, 65 of 97) showed a strong antidepressant response (≥50% improvement). Most side effects happened in the first 4 hours and were short-lived. Few infusions were…
Cognitive behavioral therapy (CBT) is one of the most-studied treatments for alcohol and drug problems. Reviews of many trials find a small but real average benefit: a meta-analysis of 53 controlled trials reported an effect size of g = 0.15 and estimated that 58% of people given CBT did better…
Treatments for depression have gotten better and far more people can get them since the 1980s. Yet the share of people in the general population with depression has not gone down. The authors call this the “treatment-prevalence paradox” and review seven possible explanations. They find little evidence that more cases…
